{
    "ticker": "EYEN",
    "name": "Eyenovia, Inc.",
    "description": "Eyenovia, Inc. is a biopharmaceutical company that focuses on developing novel therapeutics for ocular conditions using its proprietary delivery technology. Founded in 2014, Eyenovia aims to improve the efficacy and safety of treatments for eye diseases through its innovative microdose delivery platform, which allows for precise and controlled administration of drugs. The company is particularly focused on conditions such as myopia, glaucoma, and dry eye syndrome. Eyenovia's lead product candidate, MydCombi, is designed for the treatment of pupil dilation during eye examinations, and it combines two established medications into a single microdose formulation. The company's advanced development pipeline also includes additional candidates targeting other ophthalmic conditions. Eyenovia is committed to addressing unmet medical needs in the ophthalmology space and enhancing patient experiences with its user-friendly delivery systems. Their mission is to transform the treatment landscape for patients suffering from eye diseases, leveraging cutting-edge technology and a patient-centric approach.",
    "industry": [
        "Biopharmaceutical",
        "Ophthalmology"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2014",
    "website": "https://www.eyenovia.com",
    "ceo": "Eric S. Acher",
    "social_media": {
        "twitter": "https://twitter.com/EyenoviaInc",
        "linkedin": "https://www.linkedin.com/company/eyenovia/"
    },
    "investor_relations": "https://www.eyenovia.com/investors",
    "key_executives": [
        {
            "name": "Eric S. Acher",
            "position": "CEO"
        },
        {
            "name": "Michele V. B. O'Reilly",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Therapeutics",
            "products": [
                "MydCombi"
            ]
        }
    ],
    "seo": {
        "meta_title": "Eyenovia, Inc. | Innovative Ocular Therapies",
        "meta_description": "Learn about Eyenovia, Inc., a leader in developing innovative ophthalmic therapeutics using advanced microdose delivery systems. Discover their mission and product pipeline.",
        "keywords": [
            "Eyenovia",
            "Ophthalmology",
            "Biopharmaceutical",
            "MydCombi",
            "Eye Diseases",
            "Microdose Delivery"
        ]
    },
    "faq": [
        {
            "question": "What does Eyenovia focus on?",
            "answer": "Eyenovia focuses on developing innovative therapeutics for ocular conditions using its proprietary microdose delivery technology."
        },
        {
            "question": "Who is the CEO of Eyenovia?",
            "answer": "Eric S. Acher is the CEO of Eyenovia, Inc."
        },
        {
            "question": "Where is Eyenovia headquartered?",
            "answer": "Eyenovia is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Eyenovia's lead product candidate?",
            "answer": "Eyenovia's lead product candidate is MydCombi, designed for pupil dilation during eye examinations."
        },
        {
            "question": "When was Eyenovia founded?",
            "answer": "Eyenovia was founded in 2014."
        }
    ],
    "competitors": [
        "AVNR",
        "HRTX",
        "RIGL"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "INCY",
        "GILD"
    ]
}